Cogent Biosciences (COGT) Operating Leases (2019 - 2026)
Cogent Biosciences (COGT) posted quarterly Operating Leases of $14.1 million for Q1 2026, down 8.93% year-over-year from $15.5 million in Q1 2025, and down 1.8% quarter-over-quarter from $14.4 million in Q4 2025.
Cogent Biosciences (COGT) Operating Leases (2019 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Operating Leases for 8 consecutive years, with $14.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 8.93% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (down 8.93% YoY), while the FY2025 annual figure was $14.4 million, down 9.73% from the prior year.
- Operating Leases fell to $14.1 million in Q1 2026 per COGT's latest filing, from $14.4 million in the prior quarter.
- Across five years, Operating Leases topped out at $19.0 million in Q2 2022 and bottomed at $1.1 million in Q1 2022.
- Historically, Operating Leases has averaged $15.8 million across 5 years, with a median of $16.7 million in 2024.
- On a YoY basis, Operating Leases climbed as much as 2093.26% in 2022 and fell as far as 56.74% in 2022.
- Cogent Biosciences' Operating Leases stood at $18.2 million in 2022, then slipped by 4.16% to $17.5 million in 2023, then retreated by 8.96% to $15.9 million in 2024, then fell by 9.73% to $14.4 million in 2025, then retreated by 1.8% to $14.1 million in 2026.
- Business Quant data shows COGT's Operating Leases at $14.1 million in Q1 2026, $14.4 million in Q4 2025, and $14.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.32 Mn |
| Mar 31, 2026 | 14.10 Mn |
| Dec 31, 2025 | 14.36 Mn |
| Sep 30, 2025 | 14.60 Mn |
| Jun 30, 2025 | 15.05 Mn |
| Mar 31, 2025 | 15.48 Mn |
| Dec 31, 2024 | 15.90 Mn |
| Sep 30, 2024 | 16.31 Mn |
| Jun 30, 2024 | 16.71 Mn |
| Mar 31, 2024 | 17.09 Mn |
| Dec 31, 2023 | 17.47 Mn |
| Sep 30, 2023 | 17.83 Mn |
| Jun 30, 2023 | 18.18 Mn |
| Mar 31, 2023 | 18.52 Mn |
| Dec 31, 2022 | 18.23 Mn |
| Sep 30, 2022 | 18.07 Mn |
| Jun 30, 2022 | 19.01 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 831,000.00 |
| Sep 30, 2021 | 1.44 Mn |